sftd
Nasal Influenza Vaccine Flumist®, Now FDA-Approved for Children Ages 2-5
Filed in archive FDA Approvals , Influenza , Treatment by Gloria Gamat on September 20, 2007
Previously the nasal influenza vaccine Flumist® is limited to healthy children aged 5 and older and adults up to 49 years of age.

nasal_vaccine.jpg



Now, it has been recently approved by the US FDA to include children aged 2-5.

According to Jesse L. Goodman, M.D., director, FDA's Center for Biologics Evaluation and Research:

"The goal of preventing influenza is now more attainable with the availability of FluMist for younger children. This approval also offers parents and health professionals a needle-free option for squeamish toddlers, who may be reluctant to get a traditional influenza shot."


I am 34, had a C-section some 5 years ago, yet I am still squeamish of needles. While my son, almost 5, is not afraid of imaginary monster but is terrified of needles. We'll both take Flumist® anytime, which conntains a weakened form of the live virus and is sprayed in the nose.

Find more details from the FDA News.

Flumist® is a product of MedImmune Vaccines, Inc..

[Photo Credit: Nature]

Permalink: Nasal Influenza Vaccine Flumist®, Now FDA-Approved for Children Ages 2-5
Tags: Flumist  nasal  infuenza  vaccine 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/92581
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Nasal Influenza Vaccine Flumist®, Now FDA-Approved for Children Ages 2-5:

  • Currently 9.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.00 out of 1 vote(s) cast.
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!